Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, was consulted for an Nov 9 article in Street Insider, Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. Dr. El Sadr says:

“The HPTN is thrilled by these outstanding results, a milestone for the prevention of HIV among women. These findings motivate continued evaluation of the safety of CAB LA in adolescents, a group at substantial risk for HIV infection. Defining the safety of CAB LA in adolescents will hopefully lead to faster access to CAB LA, once approved for use as PrEP.”

Read the full article in Street Insider


Related Items